Analysis of Drug Authentication at the Point of Dispensing in Belgian and Greek Community Pharmacies

Abstract

Spanish

French

Background:

Authentication processes based on mass serialization technology may help to make the drug supply more secure for patients.

Objective:

To analyze the AegateProtect service, a new drug authentication service implemented in Belgian and Greek community pharmacies.

Methods:

A prospective analysis conducted via a mystery shopper audit assessed the reliability of the authentication service in a sample of Belgian community pharmacies. A retrospective analysis evaluated the effectiveness of the authentication service in Belgian and Greek community pharmacies in terms of the number of scans relating to authentic, recalled, expired, and suspicious products. Also, the costs of providing an authentication service in a hypothetical country were weighed against the benefits in terms of preventing the dispensing of substandard drugs.

Results:

The authentication service attained a sample reliability of 100% (95% CI 99.8 to 100) in Belgium. The 220,751 scans tested in Belgium during June–August 2008 consisted of authentic products (96.13% of scans), recalled products (0.74%), products that may be recalled (3.00%), and expired products (0.13%). No suspicious products were identified. Similar results were observed in Greece. For a hypothetical country, a modeling exercise showed that an authentication service would become cost-neutral in a scenario in which 0.47% of products per year are identified as recalled or expired.

Conclusions:

A drug authentication process such as the AegateProtect service is reliable and effective in identifying recalled, expired, and suspicious drugs in community pharmacies at the point of dispensing. The proportion of products identified as recalled, expired, or suspicious in a given country determines the level of cost benefits of an authentication service.

Keywords

community pharmacy costs drug authentication effectiveness mass serialization reliability

Get full access to this article

View all access options for this article.

References

Cockburn

, Newton

, Agyarko

, Akunyili

, White

. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2005; 2: e100. (accessed 2009 May 25). DOI 10.1371/journal.pmed.0020100

European Commission. Summary of community customs activities on counterfeit and piracy. Results at the European border—2007. Brussels: European Commission, 2008.

Harper

, Morris

, Satchwell

, Stevens

, Taylor

, Tremblay

. Coincidence or crisis? Prescription medicine counterfeiting. London: The Stockholm Network, 2006.

Franklin

, O'Grady

. Dispensing errors in community pharmacy: frequency, clinical significance and potential impact of authentication at the point of dispensing. Int J Pharm Pract 2007; 15:273–81.

Ball

, Douglas

. Redefining and improving patient safety. Methods Inf Med 2003; 41:271–6.

Association Pharmaceutique Belge. Liste de retrait (extraction list). Brussels: Association Pharmaceutique Belge, 2008.

National Organisation for Medicines. Recalled medicines. Athens: National Organisation for Medicines, 2008.

Frost & Sullivan. Mass serialisation in the European pharmaceutical industry. Working together on mass serialisation: whose responsibility is ensuring patient safety? London: Frost & Sullivan, 2008.

European Commission. Impact assessment. Proposal for a Directive of the European Parliament and of the Council amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of medicinal products which are falsified in relation to their identity, history or source. Brussels: European Commission, 2008.